ONO-2020
| Clinical data | |
|---|---|
| Other names | ONO2020 |
| Routes of administration | Oral[1][2] |
| Drug class | Epigenetic modulator; Immunomodulator; Cognitive enhancer |
ONO-2020 is an epigenetic modulator, immunomodulator, and possible cognitive enhancer which is under development for the treatment of agitation including due to Alzheimer's disease.[1][3][2][4] It is taken orally.[1] The drug's exact mechanism of action or biological target does not yet appear to have been disclosed.[1][3][2][4] ONO-2020 is under development by Ono Pharmaceutical.[1][3][2][4] As of May 2025, it is in phase 2 clinical trials for treatment of agitation and Alzheimer's disease.[1][3][2][4] The chemical structure of ONO-2020 does not yet appear to have been disclosed.[1]
See also
References
- 1 2 3 4 5 6 7 "ONO 2020". AdisInsight. 12 May 2025. Retrieved 10 August 2026.
- 1 2 3 4 5 "ONO-2020 Drug Profile". Ozmosi. 1 January 1900. Retrieved 10 August 2026.
- 1 2 3 4 "Delving into the Latest Updates on ONO-2020 with Synapse". Synapse. 3 June 2025. Retrieved 10 August 2026.
- 1 2 3 4 Cummings JL, Zhou Y, Yang Y, Zhong K, Fonseca J, Osse AL, et al. (2026). "Alzheimer's disease drug development pipeline: 2026". Alzheimer's & Dementia. 12 (2) e70251. New York, N. Y. doi:10.1002/trc2.70251. PMC 13140253. PMID 42095064.